Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for postoperative awakening quality and cognitive function in elderly patients with mild cognitive impairment
ChiCTR2500095570Phase 4Not yet recruiting
- Sponsor
- Cangzhou Central Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in post-operative cognitive decline (POCD), delirium and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Cangzhou Central Hospital. Primary endpoints: Quality of awakening, Postoperative cognitive function and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
post-operative cognitive decline (POCD)deliriumMild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2500095570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095570.